ArticleAmerican journal of translational research2022
Malignant adenomyoepithelioma of the breast: cases report and literature review.
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
- Malignant breast adenomyoepithelioma with diagnostic discordance: a case report and literature review.Frontiers in oncology · 2026Article
- Malignant adenomyoepithelioma of the breast with axillary lymph node metastasis: a case report and review of the literature.Frontiers in oncology · 2025Article
- Can Epithelial-Myoepithelial Carcinoma of the Breast Benefit from TROP2 Antibody-Drug Conjugate?OncoTargets and therapy · 2025Article
- A case series of adenomyoepithelioma of the breast with a case of malignant adenomyoepithelioma misinterpreted as polymorphous adenocarcinoma.AME case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant adenomyoepithelioma (MAME) of the breast is an extremely rare breast malignancy, in which they arise from either luminal epithelial or myoepithelial components, or both. At present, there is very little clinical data of MAME. CASE REPORT: We present two cases, one of them is a 34-year-old woman who underwent needle biopsy for a 3.2 cm-size mass in the right breast, and the pathology was MAME of breast. Another case is a 45-year-old woman who had a 3.0 cm-size mass in the right breast. We performed a breast-conserving surgery and sentinel lymph node biopsy, both of which were negative. The histopathology of these two cases was invasive carcinoma; however, these cases were eligible for MAME of the breast through combining with immunohistochemistry.
conclusionsMAME of the breast is very rare, and has a diverse cell morphology, which must be combined with immunohistochemistry to make a clear diagnosis. Besides, it should be differentiated from adenoid cystic cancer, malignant leafy tumor, spindle cell carcinoma, etc. The clinical characteristics and treatment strategies were further discussed in combination with the literature.
Indexed as
Identifiers
36628238PMC9827327W4315619185What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.